Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd Company History
Sun Pharma Advanced Research Company is in the business of research and development (R&D) of pharmaceutical products.
2011
"Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection".
2011
2012
SPARC - Starhaler Device finalist at Medical Design Excellence Awards
Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7
2012
2013
SPARC to provide update on NCE & NDDS programs
2013
2014
SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)
2014
2017
SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.
2017
2018
SPARC to provide progress on R&D Pipeline
Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension
SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension
Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
2018
2019
SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational
HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia
SPARC Enters into a Licensing Deal with CMS
SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044
2019
2020
Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.
Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery
SPARC to Provide Update on Clinical Programs and R&D Pipeline
2020
2021
SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037
2021
2022
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US.
2022
